Skip to main content
Premium Trial:

Request an Annual Quote

Hybrigenics Signs Three-Year, $2.4M Renewal of Protein Interaction Services Deal

Premium

French biotech firm Hybrigenics said this week that it has renewed a three-year, $2.4 million research services agreement with an unnamed US life sciences company.

Under the agreement, Hybrigenics will continue to offer its two-hybrid screens and build databases of protein interactions identified through these screens.

The new deal follows an initial three-year agreement that began in 2009. Under the new terms, the annual fee due Hybrigenics has increased from $700,000 to $790,000.

Hybrigenics has an R&D program aimed at developing treatments for diseases including prostate cancer and psoriasis, but the bulk of its revenues come from its fee-for-service protein interaction work, which is housed within its Hybrigenics Services component — a fully owned subsidiary the company created in July 2010. In the first half of 2012, its protein interaction services generated €1.4 million ($1.8 million) of the firm's total €2 million in revenues.

Clients for these services include firms like Pfizer, GlaxoSmithKline, and L'Oreal, as well as academic customers like Harvard and Johns Hopkins University.

The Scan

Billion-Dollar Diversity Initiative

The Howard Hughes Medical Institute is now accepting applications for its new $1.5 billion initiative to boost the diversity of the scientific workforce.

Biotech Co-Founder Arrested

A co-founder of a Los Angeles-based biotech company has been arrested in connection with a murder-for-hire scheme, according to Endpoint News.

Return of the Tasmanian Tiger

The Washington Post reports that a team in Australia is working to bring the thylacine back from extinction.

Nature Papers on Genome of Individual From Pompeii, CircRNA Study Best Practices, More

In Nature this week: first sequenced genome of a person from Pompeii, best practice guidelines for circRNA studies, and more.